INTRODUCTION. A randomized, parallel-group, openlabel, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. MATERIAL AND METHODS. Enrolled patients (n = 150) had received treatment with diet and exercise in the previous 3 months with HbA1c > 7 and ≤ 12%. Patients were randomized to receive monotherapy with repaglinide (n = 76) (0.5 mg/meal, maximum dose 4 mg/meal) or nateglinide (n = 74) (60 mg/meal, maximum dose 120 mg/meal) for 16 weeks. Primary and secondary efficacy end points were changes in HbA1c and fasting plasma glucose (FPG) values from baseline, respectively. Postprandial glucose...
Abstract: Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increas...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
OBJECTIVE—The purpose of this study was to evaluate the metabolic effectiveness, safety, and tolerab...
INTRODUCTION. A randomized, parallel-group, openlabel, multicenter 16-week clinical trial compared ...
Department of Endocrinology, University Hospital Maastricht, The Netherlands. bwo@sint.azm.nl OBJECT...
OBJECTIVE: Repaglinide is a newly developed oral blood glucose-lowering agent that exerts its effect...
OBJECTIVE — To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic c...
OBJECTIVE—To compare the effects of repaglinide, glipizide, and glibenclamide on insulin secretion a...
OBJECTIVE: This randomized crossover double-blind placebo-controlled study aimed to assess the effic...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
OBJECTIVE — This randomized crossover double-blind placebo-controlled study aimed to assess the effi...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
Background: In India the number of people with diabetes is increasing day-by-day. Due to a sole “Asi...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Abstract: Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increas...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
OBJECTIVE—The purpose of this study was to evaluate the metabolic effectiveness, safety, and tolerab...
INTRODUCTION. A randomized, parallel-group, openlabel, multicenter 16-week clinical trial compared ...
Department of Endocrinology, University Hospital Maastricht, The Netherlands. bwo@sint.azm.nl OBJECT...
OBJECTIVE: Repaglinide is a newly developed oral blood glucose-lowering agent that exerts its effect...
OBJECTIVE — To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic c...
OBJECTIVE—To compare the effects of repaglinide, glipizide, and glibenclamide on insulin secretion a...
OBJECTIVE: This randomized crossover double-blind placebo-controlled study aimed to assess the effic...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
OBJECTIVE — This randomized crossover double-blind placebo-controlled study aimed to assess the effi...
Repaglinide and glimepiride are relatively new oral hypoglycemic agents. Few data are available conc...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
Background: In India the number of people with diabetes is increasing day-by-day. Due to a sole “Asi...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Abstract: Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increas...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
OBJECTIVE—The purpose of this study was to evaluate the metabolic effectiveness, safety, and tolerab...